Specificity evaluation of antibodies against human β3- Adrenoceptors

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 385, Issue 9, 2012, Pages 875-882

  Cernecka, Hana ^a   Ochodnicky, Peter ^a   Lamers, Wouter H ^a   Michel, Martin C ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

3 adrenoceptors; Antibodies; Specificity

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHINESE HAMSTER; CONTROLLED STUDY; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; NONHUMAN;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CHO CELLS; CRICETINAE; CRICETULUS; EPITOPES; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, ADRENERGIC, BETA-3; TRANSFECTION;

EID: 84866740509     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-012-0767-6     Document Type: Article

References (50)

1. Anastasio NC, Lanfranco MF, Burbar MJ, Seitz PK, Stutz SJ, McGinnis AG, Watson CS, Cunningham KA (2010) Serotonin 5- HT2C receptor protein expression is enriched in synaptosomal and post-synaptic compartments of rat cortex. J Neurochem 133:1504- 1515
2. Arch JRS (2008) Perspectives from β 3-adrenoceptor agonists on pharmacology, physiology and obesity drug discovery. Naunyn- Schmiedeberg's Arch Pharmacol 378:225-240
3. Arch JR, Wilson S (1996) Prospect for beta3-adrenoceptor agonists in the treatment of obesity and diabetes. Int J Obes Relat Metab Disord 20:191-199
4. Arch JRS, Ainsworth AT, Ellis RD, Piercy V, Thody VE, Thurlby PL, Wilson C, Wilson S, Young P (1984) Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents. Int J Obes 8:1-11
5. Beermann S, Seifert R, Neumann D (2012) Commercially available antibodies against human and murine histamine H4-receptor lack specificity. Naunyn-Schmiedeberg's Arch Pharmacol 385:125-135
6. Bossard F, Silantieff E, Lavazais-Blancou E, Robay A, Sagan C, Rozec B, Gauthier C (2011) β1, β2 and β3 adrenoceptors and Na+/H+ exchanger regulatory factor 1 expression in human bronchi and their modifications in cystic fibrosis. Am J Respir Cell Mol Biol 44:91-98
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
8. Brixius K, BlochW, Ziskoven C, Bolck B, Napp A, Pott C, Steinritz D, Jiminez M, Assicks K, Giacobino JP, Schwinger RH (2006) Beta3-adrenergic eNOS stimulation in left ventricular murine myocardium. Can J Physiol Pharmacol 84:1051-1060
9. Bundgaard H, Liu C-C, Garcia A, Hamilton EJ, Huang Y, Chia KKM, Hunyor SN, Figtree GA, Rasmussen HH (2010) b3 adrenergic stimulation of the cardiac Na+-K+ pump by reversal of an inhibitory oxidative modification. Circulation 122:1699-1708
10. Chamberlain PD, Jennings KH, Paul F, Cordell J, Holmes SD, Park J, Chambers J, Sennitt MV, Stock MJ, Cawthorne MA, Young PW, Murphy GJ (1999) The tissue distribution of the human β 3- adrenoceptor studied using a monoclonal antibody: direct evidence of the β 3-adrenoceptor in human adipose tissue, atrium and skeletal muscle. Int J Obes Relat Metab Disord 23:1057-1065
11. Connacher AA, Lakie M, Powers N, Elton RA, Walsh EG, Jung RI (1990) Tremor and the anit-obesity drug BRL 26830A. Br J Clin Pharmacol 30:613-615
12. Croci T, Cecchi R, Marini P, Rouget C, Viviani N, Germain G, Guagnini F, Fradin Y, Descamps L, Pascal M, Advenier C, Breuiller-Fouche M, Leroy MJ, Bardou M (2007) In vitro and in vivo pharmacological characterization of ethyl-4-[trans-4-[((2 S)-2- hydroxy-3-[4-hydroxy-3[(methylsulfonyl)amino]- phenoxy]propyl) amino]cyclohexyl]benzoate hydrochloride (SAR150640), a new potent and selective human beta3-adrenoceptor agonist for the treatment of preterm labor. J Pharmacol Exp Ther 32:1118-1126
13. Danforth E Jr, Himms-Hagen JH (1997) Obesity and diabetes and the beta3-adrenergic receptor. Eur J Endocrinol 136:362-365
14. De Matteis R, Arch JRS, Petroni ML, Ferrari D, Cinti S, Stock MJ (2002) Immunohistochemical identification of the β 3-adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeine. Int J Obesity 26:1442-1450
15. Grol S, Nile CJ, Martinez-Martinez P, van Koeveringe GA, de Wachter SGG, de Vente J, Gillespie JI (2011) M3 muscarinic receptor like immuno-reactivity (M3-IR) in sham-operated and obstructed guinea pig bladders. J Urol 185:1959-1966
16. Grujic D, Susulic VS, Harper ME, Himms-Hagen J, Cunningham BA, Corkey BE, Lowell BB (1997) Beta3-adrenergic receptors on white and brown adipocytes mediate beta3-selective agonistinduced effects on energy expenditure, insulin secretion and food intake. A study using transgenic and gene knockout mice. J Biol Chem 272:17686-17693
17. Guillaume JL, Petitjean F, Haasemann M, Bianchi C, Eshdat Y, Strosberg AD (1994) Antibodies for the immunochemistry of the human β3-adrenergic receptor. Eur J Biochem 224:761-770
18. Hamdani N, van der Velden J (2009) Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naunyn- Schmiedeberg's Arch Pharmacol 379:403-407
19. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz K-N (2004) Comparative pharmacology of human β-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch Pharmacol 369:151-159
20. Ichimura A, Hirasawa A, Hara T, Tsujimoto G (2009) Free fatty acid receptors act as nutrient sensors to regulate energy homeostasis. Prostaglandins Lipid Med 89:82-88
21. Khullar V, Ströberg P, Anuglo J, Boerrigter P, Blauwet MB, Wooning M (2011) The efficacy and tolerability of mirabegron in patients with overactive bladder-results from a European-Australian phase III trial. Eur Urol Suppl 10:278-279
22. Kullmann FA, Limberg BJ, Artim DE, Shah M, Downs TR, Contract D, Wos J, Rosenbaum JS, De Groat WC (2009) Effects of β 3-adrenergic receptor activation on rat urinary bladder hyperactivity induced by ovariectomy. J Pharmacol Exp Ther 330:704-717
23. Kullmann FA, Downs TR, Artim DE, Limberg BJ, Shah M, Contract D, de Groat WC, Rosenbaum JS (2011) Urothelial beta-3 adrenergic receptors in the rat bladder. Neurourol Urodyn 30:144-150
24. Limberg BJ, Andersson KE, Kullmann FA, Burmer G, de Groat WC, Rosenbaum JS (2010) Beta-adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res 342:295-306
25. Lorincz A, Nusser Z (2008) Specificity of immunoreactions: the importance of testing specificity in each method. J Neurosci 28 (37):9038-9086
26. McFarlane HO, Joseph NT, Maddineni SR, Ramachandran R, Bedecarrats GY (2011) Development, validation, and utilization of a novel antibody specific to the type III chicken gonadotropinreleasing hormone receptor. Dom Animal Endocrinol 40:110-118
27. Michel MC, Vrydag W (2006) α1-, α2- and β-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147:S88-S119
28. Michel MC, Wieland T, Tsujimoto G (2009) How reliable are Gprotein- coupled receptor antibodies? Naunyn-Schmiedeberg's Arch Pharmacol 377:385-388
29. Michel MC, Ochodnicky P, Summers RJ (2010) Tissue functions mediated by β 3-adrenoceptors-findings and challenges. Naunyn-Schmiedeberg's Arch Pharmacol 382:103-108
30. Michel MC, Cernecka H, Ochodnicky P (2011a) Desirable properties of β 3-adrenoceptor agonists: implications for the selection of drug development candidates. Eur J Pharmacol 657:1-3
31. Michel MC, Ochodnicky P, Homma Y, Igawa Y (2011b) β- Adrenoceptor agonist effects in experimental models of bladder dysfunction. Pharmacol Ther 131:40-49
32. Mori A, Miwa T, Sakamoto K, Nakahara T, Ishii K (2010) Pharmacological evidence for the presence of functional β 3-adrenoceptors in rat retinal blood vessels. Naunyn-Schmiedeberg's Arch Pharmacol 382:119-126
33. Niclauß N, Michel-Reher MB, Alewijnse AE, Michel MC (2006) Comparison of three radioligands for the labelling of human β- adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch Pharmacol 374:79-85
34. Nitti V, Herschorn S, Auerbach S, Ayers S, Lee M, Martin N (2011) The efficacy and safety of mirabegron in patients with overactive bladder syndrome-results from a North-American phase III trial. Eur Urol Suppl 10:278
35. Ochodnicky P, Humphreys S, Eccles R, PoljakovicM,Wiklund P, Michel MC (2012) Expression profiling of G-protein-coupled receptors in human urothelium and related cell lines. BJU Int. doi:10.1111/j.1464-410X.2012.11145.x
36. Perfetti R, Hui H, Charnie K, Binder S, Seibert M, McLenithan J, Silver K, Walston JD (2001) Pancreatic β-cells expressing the Arg64 variant of the β 3-adrenergic receptor exhibit abnormal insulin secretory activity. J Mol Endocrinol 27:133-144
37. Petrusz P, Sar M, Ordronneau P, DiMeo P (1976) Specificity in immunocytochemical staining. J Histochem Cytochem 24:1110-1112
38. Pradidarcheep W, Stallen J, Labruyere WT, Dabhoiwala NF, Michel MC, Lamers WH (2009) Lack of specificity of commercially available antisera against muscarinic and adrenergic receptors. Naunyn-Schmiedeberg's Arch Pharmacol 379:397-402
39. Randriamboavonjy V, Badenhoop K, Schmidt H, Geisslinger G, Fisslthaler B, Fleming I (2009) The S1P2 receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes. Bas Res Cardiol 104:333-340
40. Rasmussen HH, Figtree GA, Krum H, Bundgaard H (2009) The use of beta3-adrenergic receptor agonists in the treatment of heart failure. Curr Opin Investig Drugs 10:955-962
41. Rouget C, Bardou M, Breuiller-Fouche M, Loustalot C, Naline HQE, Croci T, Cabrol D, Advenier C, Leroy MJ (2005) β 3-adrenoceptor is the predominant β-adrenoceptor subtype in human myometrium and its expression is up-regulated in pregnancy. J Clin Endocrinol Metabol 90(3):1644-1650
42. Skliris GP, Parkers AT, Limer JL, Burdall SE, Carder PJ, Speirs V (2002) Evaluation of seven oestrogen receptor β antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol 197:155-162
43. Steinle JJ, Booz GW, Meininger CJ, Day JN, Granger HJ (2003) β 3- adrenergic receptors regulate retinal endothelial cell migration and proliferation. J Biol Chem 278:20681-20686
44. Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Francon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G (2008) Stimulation of the β 3-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 33:574-587
45. Stiles GL, Benovic JL, Caron MG, Lefkowitz RJ (1984) Mammalian beta-adrenergic receptors. Distinct glycoprotein populations containing high mannose or complex type carbohydrate chains. J Biol Chem 259:8655-8663
46. Strosberg AD, Pietri-Rouxel F (1996) Function and regulation of the β 3-adrenoceptor. Trends Pharmacol Sci 17:373-381
47. Tate KM, Briend-Sutren MM, Emorine LJ, Delavier-Klutchko C, Marullo S, Strosberg AD (1991) Expression of three human β-adrenergic-receptor subtypes in transfected Chinese hamster ovary cells. Eur J Biochem 196:357-361
48. Ursino MG, Vasina V, Raschi E, Crema F, De Ponti F (2009) The β 3- adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res 59:221-234
49. Vrydag W, Michel MC (2007) Tools to study β 3-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 374:385-398
50. Yamaguchi O, Chapple CR (2007) β 3-Adrenoceptors in urinary bladder. Neurourol Urodyn 26:752-756